Press release: Humira (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
I found this press release this morning on PR Newswire:
Fifth Disease Indication for HUMIRA Provides Patients with Visible Clearance of Inflamed Skin Lesions Caused by Chronic Autoimmune Disease
ABBOTT PARK, Ill., Jan. 18 /PRNewswire-FirstCall/ — Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA(R) (adalimumab) as a treatment for adult patients with moderate to severe chronic plaque psoriasis, an autoimmune disease characterized by skin lesions that are sometimes painful and itchy. HUMIRA has been approved for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.
To read the rest of the press release, see Fifth Disease Indication for HUMIRA Provides Patients with Visible Clearance of Inflamed Skin Lesions Caused by Chronic Autoimmune Disease.
Technorati Tags: chronic plaque psoriasis,humira,adalimumab
Related Stories
POSTED IN: Autoimmune disorders (fibro, CFS, etc), Dermatologic, FDA Announcements, Medications, Press releases/Recalls/Warnings
0 opinions for Press release: Humira (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
No one has left a comment yet. You know what this means, right? You could be first!
Have an opinion? Leave a comment: